Dedifferentiated chondrosarcoma: Prognostic factors and outcome from a European group

Robert J. Grimer, Georg Gosheger, Antonie Taminiau, David Biau, Zdenek Matejovsky, Yehuda Kollender, Mikel San-Julian, Franco Gherlinzoni, Cristina Ferrari

Research output: Contribution to journalArticle

103 Citations (Scopus)

Abstract

Background: Dedifferentiated chondrosarcoma has a very poor prognosis. Because of its rarity, there are few large studies of outcome which might identify potential prognostic factors. In particular there remains uncertainty about the value of chemotherapy for this condition. Method: A retrospective study was done using data supplied by members of the European Musculo Skeletal Oncology Society (EMSOS). We obtained data on 337 patients from nine European centres with this rare condition, with details on patients, treatment and outcome which were then analysed in an attempt to identify prognostic features. Results: The median age was 59 years and there was a slight predominance of males (53%). The most common sites were the femur and pelvis. Twenty-nine percent of patients with a long bone tumour had a pathological fracture. 71 patients (21%) had metastases at the time of diagnosis and these patients had a median survival of 5 months with a 10% chance of survival at 2 years. For the 266 patients without metastases at diagnosis, 254 underwent surgery with 79% having limb salvage. Thirty-one percent of these 266 patients had chemotherapy with 47% of those under 60 receiving it. In this group of 266 patients, overall survival was 28% at 10 years and poor prognostic factors were the presence of a pathological fracture at diagnosis, a pelvic location and increasing age. Local recurrence and overall survival were related to inadequate margins of excision. We did not find that the histological subtype, size of the tumour or the use of chemotherapy significantly affected outcome. For all patients the overall survival was 24% at 5 years. Conclusions: The prognosis for patients with dedifferentiated chondrosarcoma remains dismal. Surgery with clear margins remains the principal treatment for this condition. Further use of chemotherapy should be within a trial or treatment protocol.

Original languageEnglish
Pages (from-to)2060-2065
Number of pages6
JournalEuropean Journal of Cancer
Volume43
Issue number14
DOIs
Publication statusPublished - Sep 2007

Fingerprint

Chondrosarcoma
Survival
Drug Therapy
Spontaneous Fractures
Clinical Protocols
Neoplasm Metastasis
Limb Salvage
Pelvis
Femur
Uncertainty
Neoplasms
Retrospective Studies
Outcome Assessment (Health Care)
Bone and Bones
Recurrence

Keywords

  • Chemotherapy
  • Dedifferentiated chondrosarcoma
  • Outcome
  • Prognostic factors
  • Survival

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Grimer, R. J., Gosheger, G., Taminiau, A., Biau, D., Matejovsky, Z., Kollender, Y., ... Ferrari, C. (2007). Dedifferentiated chondrosarcoma: Prognostic factors and outcome from a European group. European Journal of Cancer, 43(14), 2060-2065. https://doi.org/10.1016/j.ejca.2007.06.016

Dedifferentiated chondrosarcoma : Prognostic factors and outcome from a European group. / Grimer, Robert J.; Gosheger, Georg; Taminiau, Antonie; Biau, David; Matejovsky, Zdenek; Kollender, Yehuda; San-Julian, Mikel; Gherlinzoni, Franco; Ferrari, Cristina.

In: European Journal of Cancer, Vol. 43, No. 14, 09.2007, p. 2060-2065.

Research output: Contribution to journalArticle

Grimer, RJ, Gosheger, G, Taminiau, A, Biau, D, Matejovsky, Z, Kollender, Y, San-Julian, M, Gherlinzoni, F & Ferrari, C 2007, 'Dedifferentiated chondrosarcoma: Prognostic factors and outcome from a European group', European Journal of Cancer, vol. 43, no. 14, pp. 2060-2065. https://doi.org/10.1016/j.ejca.2007.06.016
Grimer RJ, Gosheger G, Taminiau A, Biau D, Matejovsky Z, Kollender Y et al. Dedifferentiated chondrosarcoma: Prognostic factors and outcome from a European group. European Journal of Cancer. 2007 Sep;43(14):2060-2065. https://doi.org/10.1016/j.ejca.2007.06.016
Grimer, Robert J. ; Gosheger, Georg ; Taminiau, Antonie ; Biau, David ; Matejovsky, Zdenek ; Kollender, Yehuda ; San-Julian, Mikel ; Gherlinzoni, Franco ; Ferrari, Cristina. / Dedifferentiated chondrosarcoma : Prognostic factors and outcome from a European group. In: European Journal of Cancer. 2007 ; Vol. 43, No. 14. pp. 2060-2065.
@article{f968111ac6a04614b8e494946e7f28d8,
title = "Dedifferentiated chondrosarcoma: Prognostic factors and outcome from a European group",
abstract = "Background: Dedifferentiated chondrosarcoma has a very poor prognosis. Because of its rarity, there are few large studies of outcome which might identify potential prognostic factors. In particular there remains uncertainty about the value of chemotherapy for this condition. Method: A retrospective study was done using data supplied by members of the European Musculo Skeletal Oncology Society (EMSOS). We obtained data on 337 patients from nine European centres with this rare condition, with details on patients, treatment and outcome which were then analysed in an attempt to identify prognostic features. Results: The median age was 59 years and there was a slight predominance of males (53{\%}). The most common sites were the femur and pelvis. Twenty-nine percent of patients with a long bone tumour had a pathological fracture. 71 patients (21{\%}) had metastases at the time of diagnosis and these patients had a median survival of 5 months with a 10{\%} chance of survival at 2 years. For the 266 patients without metastases at diagnosis, 254 underwent surgery with 79{\%} having limb salvage. Thirty-one percent of these 266 patients had chemotherapy with 47{\%} of those under 60 receiving it. In this group of 266 patients, overall survival was 28{\%} at 10 years and poor prognostic factors were the presence of a pathological fracture at diagnosis, a pelvic location and increasing age. Local recurrence and overall survival were related to inadequate margins of excision. We did not find that the histological subtype, size of the tumour or the use of chemotherapy significantly affected outcome. For all patients the overall survival was 24{\%} at 5 years. Conclusions: The prognosis for patients with dedifferentiated chondrosarcoma remains dismal. Surgery with clear margins remains the principal treatment for this condition. Further use of chemotherapy should be within a trial or treatment protocol.",
keywords = "Chemotherapy, Dedifferentiated chondrosarcoma, Outcome, Prognostic factors, Survival",
author = "Grimer, {Robert J.} and Georg Gosheger and Antonie Taminiau and David Biau and Zdenek Matejovsky and Yehuda Kollender and Mikel San-Julian and Franco Gherlinzoni and Cristina Ferrari",
year = "2007",
month = "9",
doi = "10.1016/j.ejca.2007.06.016",
language = "English",
volume = "43",
pages = "2060--2065",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "Elsevier Ltd",
number = "14",

}

TY - JOUR

T1 - Dedifferentiated chondrosarcoma

T2 - Prognostic factors and outcome from a European group

AU - Grimer, Robert J.

AU - Gosheger, Georg

AU - Taminiau, Antonie

AU - Biau, David

AU - Matejovsky, Zdenek

AU - Kollender, Yehuda

AU - San-Julian, Mikel

AU - Gherlinzoni, Franco

AU - Ferrari, Cristina

PY - 2007/9

Y1 - 2007/9

N2 - Background: Dedifferentiated chondrosarcoma has a very poor prognosis. Because of its rarity, there are few large studies of outcome which might identify potential prognostic factors. In particular there remains uncertainty about the value of chemotherapy for this condition. Method: A retrospective study was done using data supplied by members of the European Musculo Skeletal Oncology Society (EMSOS). We obtained data on 337 patients from nine European centres with this rare condition, with details on patients, treatment and outcome which were then analysed in an attempt to identify prognostic features. Results: The median age was 59 years and there was a slight predominance of males (53%). The most common sites were the femur and pelvis. Twenty-nine percent of patients with a long bone tumour had a pathological fracture. 71 patients (21%) had metastases at the time of diagnosis and these patients had a median survival of 5 months with a 10% chance of survival at 2 years. For the 266 patients without metastases at diagnosis, 254 underwent surgery with 79% having limb salvage. Thirty-one percent of these 266 patients had chemotherapy with 47% of those under 60 receiving it. In this group of 266 patients, overall survival was 28% at 10 years and poor prognostic factors were the presence of a pathological fracture at diagnosis, a pelvic location and increasing age. Local recurrence and overall survival were related to inadequate margins of excision. We did not find that the histological subtype, size of the tumour or the use of chemotherapy significantly affected outcome. For all patients the overall survival was 24% at 5 years. Conclusions: The prognosis for patients with dedifferentiated chondrosarcoma remains dismal. Surgery with clear margins remains the principal treatment for this condition. Further use of chemotherapy should be within a trial or treatment protocol.

AB - Background: Dedifferentiated chondrosarcoma has a very poor prognosis. Because of its rarity, there are few large studies of outcome which might identify potential prognostic factors. In particular there remains uncertainty about the value of chemotherapy for this condition. Method: A retrospective study was done using data supplied by members of the European Musculo Skeletal Oncology Society (EMSOS). We obtained data on 337 patients from nine European centres with this rare condition, with details on patients, treatment and outcome which were then analysed in an attempt to identify prognostic features. Results: The median age was 59 years and there was a slight predominance of males (53%). The most common sites were the femur and pelvis. Twenty-nine percent of patients with a long bone tumour had a pathological fracture. 71 patients (21%) had metastases at the time of diagnosis and these patients had a median survival of 5 months with a 10% chance of survival at 2 years. For the 266 patients without metastases at diagnosis, 254 underwent surgery with 79% having limb salvage. Thirty-one percent of these 266 patients had chemotherapy with 47% of those under 60 receiving it. In this group of 266 patients, overall survival was 28% at 10 years and poor prognostic factors were the presence of a pathological fracture at diagnosis, a pelvic location and increasing age. Local recurrence and overall survival were related to inadequate margins of excision. We did not find that the histological subtype, size of the tumour or the use of chemotherapy significantly affected outcome. For all patients the overall survival was 24% at 5 years. Conclusions: The prognosis for patients with dedifferentiated chondrosarcoma remains dismal. Surgery with clear margins remains the principal treatment for this condition. Further use of chemotherapy should be within a trial or treatment protocol.

KW - Chemotherapy

KW - Dedifferentiated chondrosarcoma

KW - Outcome

KW - Prognostic factors

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=34548479957&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34548479957&partnerID=8YFLogxK

U2 - 10.1016/j.ejca.2007.06.016

DO - 10.1016/j.ejca.2007.06.016

M3 - Article

C2 - 17720491

AN - SCOPUS:34548479957

VL - 43

SP - 2060

EP - 2065

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

IS - 14

ER -